Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia
- PMID: 20083009
- DOI: 10.1016/S1353-8020(09)70782-5
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia
Abstract
The development of L-DOPA-induced dyskinesia (LID) is attributed to plastic responses triggered by dopamine (DA) receptor stimulation in the parkinsonian brain. This article reviews studies that have uncovered different levels of maladaptive plasticity in animal models of LID. Rats developing dyskinesia on chronic L-DOPA treatment show abnormal patterns of signaling pathway activation and synaptic plasticity in striatal neurons. In addition, these animals show a gene expression profile indicative of structural cellular plasticity, including pronounced upregulation of genes involved in extracellular matrix remodeling, neurite extension, synaptic vesicle trafficking, and endothelial and cellular proliferation. Structural changes of neurons and microvessels within the basal ganglia are currently being unraveled by detailed morphological analyses. The structural and functional adaptations induced by L-DOPA in the brain can be viewed as an attempt to meet increased metabolic demands and to boost cellular defense mechanisms. These homeostatic responses, however, also predispose to the appearance of dyskinesia and other complications during the course of the treatment.
Similar articles
-
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.Neurobiol Dis. 2009 Oct;36(1):116-25. doi: 10.1016/j.nbd.2009.07.002. Epub 2009 Jul 15. Neurobiol Dis. 2009. PMID: 19615446
-
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Prog Brain Res. 2008. PMID: 18772047 Review.
-
Molecular mechanisms of l-DOPA-induced dyskinesia.Int Rev Neurobiol. 2011;98:95-122. doi: 10.1016/B978-0-12-381328-2.00004-3. Int Rev Neurobiol. 2011. PMID: 21907084 Review.
-
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.Neurobiol Dis. 2008 Feb;29(2):327-35. doi: 10.1016/j.nbd.2007.10.001. Epub 2007 Oct 11. Neurobiol Dis. 2008. PMID: 17997101
-
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.Exp Neurol. 2005 Jul;194(1):66-75. doi: 10.1016/j.expneurol.2005.02.002. Exp Neurol. 2005. PMID: 15899244
Cited by
-
Unveiling differential gene co-expression networks and its effects on levodopa-induced dyskinesia.iScience. 2024 Aug 26;27(9):110835. doi: 10.1016/j.isci.2024.110835. eCollection 2024 Sep 20. iScience. 2024. PMID: 39297167 Free PMC article.
-
Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.ACS Chem Neurosci. 2013 May 15;4(5):747-60. doi: 10.1021/cn300234z. Epub 2013 Apr 1. ACS Chem Neurosci. 2013. PMID: 23496922 Free PMC article.
-
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.Neurotox Res. 2020 Jan;37(1):12-29. doi: 10.1007/s12640-019-00109-8. Epub 2019 Oct 22. Neurotox Res. 2020. PMID: 31637586 Review.
-
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.Drug Des Devel Ther. 2016 Feb 3;10:547-55. doi: 10.2147/DDDT.S93487. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26893543 Free PMC article.
-
Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.Front Neurol. 2014 Aug 18;5:157. doi: 10.3389/fneur.2014.00157. eCollection 2014. Front Neurol. 2014. PMID: 25183959 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources